ArticleBioactive materials2026
Materialogenetics: an emerging and promising framework for cell-specific genetic manipulation.
Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetic manipulation technologies (GMTs) serve as potent instruments for elucidating the molecular and cellular mechanisms that underly both physiological and pathological processes. However, the increasing recognition of the cellular heterogeneity in terms of their spatial distribution, cellular subtypes, and functional states in complex tissues, has posed new challenges to the applicability and precision of these technologies. While current GMTs facilitate precise genetic interventions at the molecular level, their capacity for achieving cell-specific genetic regulation remains constrained. In this context, we utilize research on fibroblast growth factors (FGFs)/FGF receptors (FGFRs) signaling in osteoarthritis (OA) as a case to demonstrate the technical limitations faced by existing GMTs. To address these constraints, we propose a conceptual framework termed Materialogenetics, which integrates advances in biomaterials science with genetic manipulation approaches. Advanced biomaterials with active-targeting and stimuli-responsive properties have been widely explored in disease diagnosis and therapy. When combined with GMTs, these materials can theoretically greatly improve cell-specific and spatiotemporally controlled genetic manipulation at both molecular and cellular levels. Moreover, biomaterial-assisted genetic manipulation offers several practical advantages, including cost-effectiveness, operational simplicity, and a high degree of tunability, rendering the platform highly adaptable to a wide range of research contexts. Collectively, Materialogenetics establishes a conceptual framework that bridges the fields of materials science and genetics, representing a versatile and promising platform for achieving precise genetic manipulation in complex biological systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.